The Rheumatologist reports the sessions at the 2019 ACR/ARP Annual Meeting will include more conversation-style discussions and fewer lectures from lecturers. Workshops titled, ‘Meet the Professor’ will cover cutting edge topics, to spark dialogue among experts in their field.

The Rheumatologist spoke to Anne R. Bass, MD, rheumatologist at HSS, and speaker of the Checkpoint Inhibitors ‘Meet the Professor’ course, explained how the focus of the session might be beneficial to rheumatologists who see patients with immunotherapy-associated arthritis symptoms (which often mimic those of rheumatoid arthritis). “Checkpoint inhibitors are being used to treat an ever-expanding list of cancers. Whether you work in an academic center or in private practice, you are likely to see patients experience immune-related adverse events from these powerful medications, including checkpoint inhibitor-associated arthritis,” said Dr. Bass. “Treatment has to balance arthritis control with maintaining the checkpoint inhibitor’s anti-cancer effect. Identifying the safest disease-modifying anti-rheumatic drugs and biologics to use in this setting is a research priority,” she added.

Read the full article at the-rheumatologist.org.